NuVasive (NUVA) PT Raised to $85 at Cowen

Cowen analyst Joshua Jennings raised the price target on NuVasive (NASDAQ: NUVA) to $85.00 (from $75.00) while maintaining an Outperform rating.

The analyst commented, "NUVA will likely announce its 2019 results at an industry conference next week. We foresee no negative surprises for the 4Q performance or 2020 guidance. In recognition of NUVA's vastly improved operating consistency, we're increasing the multiples we assign to its stock, which yields our new $85 target. NUVA continues to show a valuation disconnect with spine peer GMED that should narrow in time."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins